-
Citi Rates Mylan (MYL) A High Risk Buy
Tuesday, June 8, 2010 - 10:04am | 225Read More...Citi Investment Research & Analysis analysts John Boris, Morten Marott, Timothy W Chou and Nirav Jhaveri maintained their Buy/High Risk rating for shares of Mylan Inc (Nasdaq: MYL), with a price target of $23 per share. The analysts said that Mylan Inc is currently trading near the bottom of...
-
Citi Sees EPS Growth For Teva Pharmaceutical Industries (TEVA)
Friday, May 28, 2010 - 11:57am | 227Read More...Citi Investment Research & Analysis analysts John Boris, Morten Marott, Timothy W Chou and Nirav Jhaveri rated shares of Teva Pharmaceutical Industries (Nasdaq: TEVA) a Buy, with a price target of $72 per share. The analysts noted that Teva Pharmaceutical Industries recently reiterated that its...
-
Citi Says Mylan (MYL) Shares Are A Buy
Friday, May 28, 2010 - 11:29am | 187Read More...Citi Investment Research & Analysis analysts John Boris, Morten Marott, Timothy W Chou and Nirav Jhaveri rated shares of Mylan Inc (Nasdaq: MYL) a Buy, with a target price of $23 per share. The analysts said that the management of Mylan Inc said that pricing pressure on European generic drugs...
-
Citi Sees Strong Upside At Watson Pharmaceuticals (WPI)
Friday, May 28, 2010 - 11:10am | 197Read More...Citi Investment Research & Analysis analysts John Boris, Morten Marott, Timothy W Chou and Nirav Jhaveri rated shares of Watson Pharmaceuticals Inc (NYSE: WPI) a Buy, with a price target of $48 per share. The analysts said that they still expect to see a strong 2011 from Watson Pharmaceuticals...
